New antibody trial aims to ease core autism symptoms

NCT ID NCT06500637

Recruiting now Symptom relief Sponsor: Rossignol Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests whether TB006, an antibody that targets a protein called Galectin-3, can improve core symptoms of autism in adults aged 18 to 35. Forty-five participants will be randomly assigned to receive either TB006 or a placebo for 14 weeks, with an open-label extension for those on placebo. The study measures changes in autism severity using clinician-rated scales and neurodevelopmental assessments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TB006 (a monoclonal antibody targeting Galectin-3)
What this could lead to: If successful, this could point toward a new treatment option for core autism symptoms in adults.
What could go wrong: This is an early Phase 2 trial with only 45 participants, so results may not apply broadly. The drug may not show significant benefit over placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTISM SPECTRUM DISORDER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Rossignol Medical Center
RECRUITING

Phoenix, Arizona, 85050, United States

Contact Email: •••••@•••••
Rossignol Medical Center
RECRUITING

Aliso Viejo, California, 92656, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.